SCHEMBL11029418

SCHEMBL11029418

COc1ccc(CN2Cc3c(Nc4ccc(OCc5ccccc5)cc4)ccnc3NC2=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.44
GRM2 Q14416 1/20 0.41
SIRT2 Q8IXJ6 1/20 0.41
FAAH O00519 1/20 0.41
MGLL Q99685 1/20 0.41
HTT P42858 3/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PTK6 Q13882 1/20 0.40
MMP13 P45452 1/20 0.40
EGFR P00533 3/20 0.39
ERBB2 P04626 2/20 0.39
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11029374 0.86 KDM4E (0.43) IDH1ALDH1A1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL1161182 0.86 AURKA (0.51) FAAHMGLLMAPTEGFRLMNA
SCHEMBL11886916 0.85 GAA (0.40) IDH1ALDH1A1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL11032433 0.80 EPHX2 (0.46) ALDH1A1MAPTGAA
SCHEMBL11030470 0.80 ROCK2 (0.51)
SCHEMBL11039120 0.80 MAPK10 (0.47) IDH1SMN1; SMN2GAALMNA
SCHEMBL11032474 0.79 PDGFRA (0.43) HTTALDH1A1MAPTSMN1; SMN2GAA
SCHEMBL11028642 0.78 MAPT (0.43) HTTALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL1160975 0.76 GAA (0.50) IDH1GRM2ALDH1A1CYP1A2MAPT
SCHEMBL11031294 0.76 KDM4E (0.45) ALDH1A1MAPTSMN1; SMN2GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569295-B2 Bicyclic urea compounds MERCK PATENT GMBH (DE) 2013-10-29 US disclosed
US-8569295-B2 Bicyclic urea compounds MERCK PATENT GMBH (DE) 2013-10-29 US disclosed
US-8569295-B2 Bicyclic urea compounds MERCK PATENT GMBH (DE) 2013-10-29 US disclosed
EP-2461869-B1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2013-08-21 EP disclosed
US-20120190654-A1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2012-07-26 US disclosed
US-20120190654-A1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2012-07-26 US disclosed
US-20120190654-A1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2012-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190654-A1 NOVEL BICYCLIC UREA COMPOUNDS CCNC, CCNI, CCNA1 IDH1 747/4885GRM2 4731/4885SIRT2 961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.